Sjögren’s syndrome and pancreatic affection

Gabriela Hernández-Molina,* Martha L. Michel-Peregrina

Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

A R T I C L E  I N F O

Article history:
Received April 20, 2010
Accepted July 20, 2010

Keywords:
Sjögren’s Syndrome
Exocrine pancreas

A B S T R A C T

Sjögren’s syndrome (SS) is an autoimmune disorder affecting primarily the exocrine glands, leading to keratoconjunctivitis sicca (KCS) and xerostomia, but that can also include extraglandular features. Due to the anatomical, physiological and pathological similarity between the pancreas and the salivary glands, it has been described that the pancreas is not exempt from the damage produced by this syndrome. Some authors have assessed pancreatic involvement of SS by analyzing the histopathological changes, evaluating the pancreatic endocrine and exocrine function (serum pancreatic enzymes, elastase, lipase or trypsin determinations, N-benzoyl-L-tyrosyl-para-aminobenzoic acid excretion test, etc), searching specific pancreatic antibodies (antiductal) or performing endoscopic retrograde colangiopancreatography or noninvasive imaging studies such as computed tomography or ultrasound. Herein we review the literature regarding the prevalence and type of pancreatic involvement in the SS and we discuss the differential diagnosis with multiorgan lymphoproliferative Syndrome.

© 2010 Elsevier España, S.L. All rights reserved.

Afección pancreática en el síndrome de Sjögren

R E S U M E N

El síndrome de Sjögren (SS) es una enfermedad autoinmunitaria que afecta principalmente a las glándulas exocrinas, aunque puede ocasionar también manifestaciones extraglandulares. Dada la similitud anatómica, fisiológica y patológica del páncreas y las glándulas salivales, se ha descrito que el páncreas no está exento del daño producido por el síndrome de Sjögren. Por esta similitud, algunos autores han estudiado la influencia del SS en el páncreas analizando los cambios histopatológicos, evaluando la función pancreática endocrina y exocrina (medición de enzimas pancreáticas séricas, prueba de excreción de ácido N-benzoyl-L-tyrosil-para-aminobenzoico, medición de elastasa, lipasa o trypsin), por la detección de anticuerpos específicos para páncreas (Ac. anticonductos), o mediante la realización de colangiopancreatografía endoscópica retrógrada o estudios de imagen no invasivos (tomografía computarizada y ultrasonido). En el presente trabajo revisamos la literatura científica en relación con la prevalencia y el grado de afección pancreática en SS y discutimos sobre el diagnóstico diferencial con el síndrome linfoproliferativo multiorgánico.

© 2010 Elsevier España, S.L. Todos los derechos reservados.

Sjögren’s syndrome (SS) is an autoimmune disease involving exocrine glands whose clinical spectrum may also include extraglandular symptoms. It mainly affects salivary and lachrymal glands and leads to the occurrence of keratoconjunctivitis sicca and xerostomia due to focal lymphocytic infiltration. This condition is considered primary (pSS) when the clinical manifestations occur in isolation, and secondary (sSS) when they are associated with another autoimmune disease. Gastrointestinal tract affection has also been described among the manifestations of this syndrome. Since the pancreas is, in part, an exocrine gland, it is not free from being affected in these patients. In this work, we review the literature with regard to pancreatic involvement in SS.

Clinical presentation

Pancreatic manifestations in patients with pSS are diverse. For example, in the largest series of patients with pSS (1,010 patients),
there was a 0.5% prevalence of acute pancreatitis of any aetiology. On the other hand, the coexistence of pSS with autoimmune pancreatitis, retroperitoneal fibrosis and sclerosing cholangitis is well-known, although its prevalence is unknown because the scientific literature includes only case reports. In addition, no information on the frequency of chronic pancreatitis in these patients is available. We evaluated the clinical records of 97 patients with pSS from our institution, a tertiary referral centre for patients with rheumatic diseases, and found that 3 patients (3%) presented autoimmune pancreatitis, of which 2 subjects progressed to chronic pancreatitis (unpublished data).

As for the time of presentation of both diseases (autoimmune pancreatitis and SS), in several of the cases reported in scientific literature, the diagnosis of SS was established after that of gastrointestinal autoimmune disease. However, it is really not known whether the patients presented prior sicca symptoms since they were not intentionally evaluated in relation to it. Some other reports have described simultaneous presentation of both autoimmune diseases.

Another presentation of pancreatic disease, although described in rare cases in these patients, is the presence of pancreatic pseudotumor. In these cases, the initial suspicion was of malignant pancreatic neoplasm given the presence of a pancreatic mass. However, after resection of the surgical specimen, an infiltration of mononuclear cells, lymphocytes and plasma cells was documented, as well as glandular atrophy and fibrosis.

**Anti-ductal antibodies**

Due to the similarity of the pancreas with other exocrine glands (salivary gland) and the bile duct and distal renal tubule, the presence of antibodies against antigens of ductal cells has been studied in patients with pSS, autoimmune chronic pancreatitis and in patients with both entities. Ludwig et al. demonstrated the presence of antibodies against salivary duct epithelial cells in a study involving 12 patients with SS and 31 patients with rheumatoid arthritis. The authors found positivity for these antibodies in 41% of patients with SS and 33% of patients with rheumatoid arthritis. The presence of these antibodies was not detected in a control group. All sera positive for this antibody presented a positive intra- and inter-lobular immunofluorescence reaction to human and monkey pancreatic duct cells. These sera also presented positive staining in parotid, submandibular and lachrymal tissue from healthy controls, pancreatic duct cells. These sera also presented positive staining in parotid, submandibular and lachrymal tissue from healthy controls. For example, in a study which included 25 patients with pSS, 24% presented hyperamylasemia of isotype P and S, probably indicating a moderate subclinical inflammatory process. Higher values of trypsinogen have also been documented in these patients. Consequently, since the elevation of pancreatic enzymes is a common finding, the monitoring of these values has been recommended in patients with SS to identify damage in its early stages; the most specific is the value of trypsin. Ostuni et al. also found a relationship between the values of total amylase and pancreatic isoamylase with serum values of 2-microglobulin and they correlated pancreatic isoamylase with the presence of abnormalities in salivary gland scintigraphy.

**Histopathology**

Pancreatic morphological changes have been described in post mortem studies of patients with pSS in whom pancreatic problems had not been previously documented. These changes include moderate levels of chronic pancreatitis, atrophy, replacement of pancreatic tissue by vascular connective tissue and lymphocytic infiltration. In a report of 3 autopsied patients with pSS who were known to suffer pancreatic dysfunction, histopathological findings were similar to those reported previously in cases of asymptomatic patients.

Furthermore, biopsies from patients with autoimmune pancreatitis reported findings similar to those described in salivary glands from patients with autoimmune sialadenitis.

**Imaging studies of the pancreas**

There are few studies that have evaluated the pancreas in patients with autoimmune diseases in general through imaging techniques. Sahani et al. conducted a study that assessed patients with autoimmune pancreatitis (4 of them with other autoimmune diseases, including SS) via computed tomography (CT) prior to steroid therapy. The CTs showed diffuse pancreatic inflammation with loss of lobularity in most patients. Moreover, the presence of an enlarged pancreatic size in 90% of cases was documented in a series of patients with chronic pancreatitis and SS who were evaluated by CT or ultrasound.

When evaluating a group of 20 patients with SS by endoscopic retrograde cholangiopancreatography (ERCP), abnormalities were located in the pancreatic duct in 27% of patients, although these alterations were mild in the pancreatic duct branches and absent in the main pancreatic duct. Conversely, in a study which included a group of patients with SS and elevation of pancreatic enzymes, none of them presented any alteration in the morphology of the pancreas assessed by CT.

Recently, an evaluation of 12 asymptomatic pSS patients by magnetic resonance cholangiography reported that 3 of them presented morphological changes in the pancreatic duct and 2 of them presented abnormalities suggestive of chronic pancreatitis.

**Pancreatic function**

**Exocrine function**

Given the anatomical, physiological and pathological similarities between the salivary and pancreatic glands, it has been postulated that pancreatic function is likely to be also impaired in patients with SS. However, the presence of symptoms of pancreatic failure has rarely been documented, so it is suggested that in these patients, if pancreatic failure is indeed present, it is mild.

In this regard, several authors have studied patients with SS, either primary or secondary (associated with rheumatoid arthritis), using various diagnostic tests: stimulation with secretin and ERCP quantification of the volume of duodenal secretion, with or without measurement of bicarbonate concentration, determination of fat in faeces, N-benzoyl-L-tyrosyl para-amo benzoic acid (PABA) excretion test and measurement of elastase, lipase or trypsin (Table 1).

<table>
<thead>
<tr>
<th>Test</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secretin stimulation test</td>
<td>Test of choice for the detection of exocrine pancreatic failure.</td>
</tr>
<tr>
<td>ERCP</td>
<td>Quantification of the volume of duodenal secretion.</td>
</tr>
<tr>
<td>Bicarbonate concentration</td>
<td>Measurement of bicarbonate concentration.</td>
</tr>
<tr>
<td>Fat in faeces</td>
<td>Measurement of fat in faeces.</td>
</tr>
<tr>
<td>N-benzoyl-L-tyrosyl para-amo benzoic acid (PABA) excretion test</td>
<td>Test for measurement of PABA excretion.</td>
</tr>
<tr>
<td>Elastase, lipase or trypsin</td>
<td>Measurement of enzymes.</td>
</tr>
</tbody>
</table>
of the collection of duodenal and/or pancreatic juices by ERCP after stimulation with secretin. Because it is an invasive procedure as well as technically difficult and not free from complications, other alternatives have been sought, such as faecal elastase measurement, chymotrypsin, determination of lipase, pancreolauryl test, bentiromide test or PABA excretion. Unfortunately, the results of these tests are variable and sometimes contradictory; for example, findings have included an absence of involvement in pancreatic exocrine function, chymotrypsin, determination of lipase, pancreolauryl test, bentiromide test or PABA excretion. Unfortunately, the results of these tests are variable and we must not forget that, in general, they are mainly useful for detecting cases of advanced pancreatic failure.

Those pancreatic function studies in SS mentioned previously (Table 1) have shown variable and sometimes contradictory results; for example, findings have included an absence of involvement in pancreatic exocrine function, chymotrypsin, determination of lipase, pancreolauryl test, bentiromide test or PABA excretion. Unfortunately, the results of these tests are variable and we must not forget that, in general, they are mainly useful for detecting cases of advanced pancreatic failure.

Table 1

Exocrine function studies in Sjögren syndrome

<table>
<thead>
<tr>
<th>Author</th>
<th>Test</th>
<th>Population</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fenster et al, 1964</td>
<td>Stimulation with secretin</td>
<td>n=11 SS</td>
<td>&lt; duodenal volume in SS versus controls</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n=8 controls</td>
<td>In 3 patients, SS was considered the abnormal test; all asymptomatic</td>
</tr>
<tr>
<td>Hradsky et al, 1967</td>
<td>Pancreozymin stimulation</td>
<td>n=20 pSS</td>
<td>90% alteration in the test</td>
</tr>
<tr>
<td></td>
<td>Stimulation with secretin</td>
<td>n=23 pSS</td>
<td>Pancreatic failure in 48% of patients</td>
</tr>
<tr>
<td></td>
<td>BT-PABA</td>
<td>n=16 SS</td>
<td>BT-PABA alterations in 37.5% of SS patients, 35% of RA and 0% of controls</td>
</tr>
<tr>
<td></td>
<td>Measurement of trypsinogen</td>
<td>n=20 RA</td>
<td>&gt; trypsin</td>
</tr>
<tr>
<td></td>
<td>BT-PABA</td>
<td>n=11 pSS</td>
<td>Moderate abnormality in 27%</td>
</tr>
<tr>
<td></td>
<td>Serum trypsin</td>
<td>n=8 SS + RA</td>
<td>Alterations in 63% in some test. No differences between pSS and sSS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n=30 controls</td>
<td>In 21% &lt; BT-PABA and &gt; trypsin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In 42% normal BT-PABA and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt; pancreatic function associated to a longer disease duration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 patients presented steatorrhoea</td>
</tr>
<tr>
<td>Nelly et al, 1993</td>
<td>BTP test</td>
<td>n=12 pSS with abdominal pain/diarrhoea</td>
<td>No alterations in the test</td>
</tr>
<tr>
<td>Nichimori et al, 1995</td>
<td>Serum trypsin</td>
<td>n=12 asymptomatic pSS</td>
<td>&gt; trypsin level in symptoms</td>
</tr>
<tr>
<td></td>
<td>BT-PABA</td>
<td>n=20 pSS</td>
<td>50% pSS, 35% PBC and 36% both entities presented an increase of at least one pancreatic enzyme</td>
</tr>
<tr>
<td></td>
<td>Measurement of elastase,</td>
<td>n=17 PBC</td>
<td>&lt; excretion of BT-PABA in 18% pSS, 25% PBC</td>
</tr>
<tr>
<td></td>
<td>lipase and trypsin</td>
<td>n=11 pSS + PBC</td>
<td>Minimal changes in pancreatic duct in 27% pSS, 22% PBC and 75% both. 6 patients with SS and intermittent light abdominal pain</td>
</tr>
<tr>
<td>Ostuni et al, 1996</td>
<td>Pancreatic enzymes</td>
<td>n=77 pSS</td>
<td>All negative to anti-ductal Ab.</td>
</tr>
<tr>
<td></td>
<td>Anti-ductal antibodies CT</td>
<td>n=70 controls</td>
<td>&gt; level of pancreatic enzymes in pSS versus a control</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In pSS: 35.1% elevation of trypsin, 26% &gt; pancreatic isoaonymase, 20% total amylase</td>
</tr>
<tr>
<td>D'Ambrosi et al, 1997</td>
<td>Secretion with secretin</td>
<td>n=11pSS</td>
<td>Normal CT (carried out in 20 patients).</td>
</tr>
<tr>
<td></td>
<td>and caerulein</td>
<td></td>
<td>29% patients with intermittent abdominal pain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>54% pSS and 27.2% RA + SS had &lt; duodenal volume, concentration of bicarbonate and trypsin</td>
</tr>
<tr>
<td>Afzelius et al, 2010</td>
<td>Secretin test by magnetic</td>
<td>n=11 RA + SS</td>
<td>25% morphological alteration. 2 patients with changes of chronic pancreatitis</td>
</tr>
<tr>
<td></td>
<td>resonance cholangiography</td>
<td>n=12 pSS</td>
<td>20% slight decrease in exocrine function.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>One patient presented diarrhoea and 4, infrequent slight abdominal pain</td>
</tr>
</tbody>
</table>

BTP indicates benzoyl-tripeptide test; BT-PABA, n-benzoyl-l-tyrosyl-para-aminobenzoic acid; CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; PBC, primary biliary cirrhosis; pSS: primary SS; SS: Sjögren syndrome; sSS: secondary Sjögren syndrome.

It is known that the non-obese mouse model for diabetes mellitus type 1 (DM-1) also presents sialadenitis at 4-6 months of age. Deficiency of E2F1, regulator of the proliferation, differentiation and apoptosis of T cells, induces the early appearance of diabetes and SS in this animal model. However, although theoretically the
A new entity has recently been proposed to cover those pathologies that have documented elevations of serum IgG4 values, infiltrations of plasma cells and IgG4+ monocytes in the affected organs. This entity is known as IgG4-positive multi-organ lymphoproliferative syndrome and may be multisystem or affect a single organ. The most frequently involved organs are the pancreas, biliary tract, liver, kidneys, lungs, aorta and exocrine glands, etc.

With the introduction of this new concept, it is likely that some of the patients described previously in the scientific literature, in whom SS coexists with other autoimmune diseases (pancreatitis, cholangitis, thyroiditis, etc.), are in fact cases of IgG4 syndrome.

Conclusions

Although the pancreas is a gland very similar to the salivary glands, clinical involvement of the pancreas is one of the most frequent manifestations of SS. Studies in this area are few and most of them were carried out more than two decades ago, with mixed results due to differing methodologies and having included only a small number of patients. The most frequently reported findings were alterations of pancreatic enzymes and pancreatic exocrine dysfunction; however, the latter was mild and, therefore, subclinical. These changes could not be correlated to morphological or imaging changes. In addition, pancreatic endocrine involvement has been attributed more to external factors than to the autoimmune disease itself. Common antibodies that recognise the pancreas and salivary glands have also been identified; however, the detection of these antibodies has not yet become widespread in clinical practice.

Lastly, the relationship between autoimmune pancreatitis and Mikulicz disease has been highlighted, encompassing both pathologies in a new entity: IgG4-positive multi-organ lymphoproliferative syndrome. Consequently, this new concept requires consideration of the idea that the coexistence of autoimmune pancreatitis in patients with SS represents, in fact, a single entity.

Conflict of interest

The authors declare no conflict of interest.

References

10. Nishimori I, Okazaki K, Yamamoto Y, Morita M, Tamura S, Yamamoto Y. Specific cellular immune responses to pancreatic antigen in chronic pancreaticitis ad